NCT03865082View on ClinicalTrials.gov

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

April 30, 2022

Conditions
Solid Tumor
Interventions
DRUG

Tilsotolimod

9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.

DRUG

Nivolumab

Specified dose on specified days.

DRUG

Ipilimumab

Specified dose on specified days.

Trial Locations (3)

77030

MD Anderson Cancer Center, Houston

85719

Banner University Medical Center Tucson Campus, Tucson

92663

University of Southern California/ Hoag Hospital Presbyterian, Newport Beach

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Idera Pharmaceuticals, Inc.

INDUSTRY

NCT03865082 - Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Biotech Hunter | Biotech Hunter